Orion: The Nubeqa Royalty Is Maxed, the Optionality Is Just Starting

A 28% sales jump and an early DASL-HiCaP win are real; the more interesting signal is the quiet rewiring of supply chain and org chart before 2033.

ORNBV.HE · Earnings Call · 2026-10-28

The Blowout Is Nubeqa; the Surprise Is Timing

Orion's Q3 was not subtle. Net sales rose 28% to EUR 542 million, operating profit jumped almost 74% to EUR 210 million, and management raised full-year guidance to EUR 2.070-2.140 billion of sales and EUR 730-790 million of operating profit. The engine is familiar: Nubeqa royalties and product sales reached EUR 280 million in the quarter, with EUR 222 million of royalties and EUR 58 million of tablet sales to Bayer. After nine months, Innovative Medicines is already almost half of group revenue. The genuinely new item was the DASL-HiCaP interim result. Bayer reported at ESMO that darolutamide plus androgen deprivation therapy and radiotherapy cut the risk of metastasis or death by 58% versus placebo. That is a meaningful early-line prostate-cancer signal, and it arrived ahead of schedule. On the prior call, management had said the readout was estimated in 2028: “This relates to the DASL-HiCaP study and the readout for this study, if I remember correctly, it's '28.” — Liisa Hurme, CEO · 2026-04-23 The early look does not change near-term numbers, but it does change the shape of the long-term Nubeqa option.

interim results ... demonstrated 58% reduction of the risk of metastasis or death with darolutamide and androgen deprivation therapy and radiotherapy versus placebo and androgen deprivation therapy and radiotherapy.
Liisa Hurme, Chief Executive Officer · 2026-10-28

The Royalty Math Is Maxed; the Option Value Is Not

The quarter's central tension is that Orion's biggest cash engine is now mechanically simple. The maximum royalty tier was reached in Q2, so Q4 royalties should track Bayer's end-market sales rather than benefit from another step-up. That is why the guidance range remains wide. “the biggest reason for a wide range still is Nubeqa ... Q4 is thereby estimated to be our best quarter also for Nubeqa.” — Rene Lindell, Chief Financial Officer · 2026-10-28 The market already knows this. What it does not yet know is how much the DASL-HiCaP opportunity is worth to Orion, because the company has an opt-in right that would be exercised if and when Bayer files for marketing approval. Management explicitly declined to update the greater-than-EUR 1 billion Nubeqa sales ambition by the end of the decade, even though that ambition already includes early-line expansion. That is the right posture, but it leaves a gap between clinical excitement and financial disclosure. The Nubeqa royalty is no longer a growth-on-autopilot story; it is a market-growth story with a call option on earlier lines. The higher royalty rate has already done its work. Analysts pressed on whether royalties looked soft versus consensus; CFO Rene Lindell attributed some of that to the normal estimation of the last month of the quarter. The takeaway is not that Nubeqa is slowing, but that the quarterly royalty line will be noisier now that the rate is capped.

The Supply Chain Is Being Rewired -- Quietly

The most underappreciated strategic shift is in manufacturing. Orion is adding a U.S. contract manufacturer for darolutamide API, alongside Hanko and Germany, to manage supplier risk as volumes outgrow original assumptions. “when we see that the volumes have been growing much faster and higher than originally was estimated, it's important to manage your supplier risks.” — Liisa Hurme, Chief Executive Officer · 2026-10-28 That is a practical response to Nubeqa concentration, and it also gives Orion a potential tariff hedge. But it is a contrast with the prior stance. In July 2025, management said: “right now, we don't have any intentions to set up manufacturing capacity in U.S.” — Liisa Hurme, CEO and President · 2025-07-21 Orion is not building its own U.S. plant; it is using contract manufacturing. Still, the posture has moved from wait-and-see to active supply-chain redundancy. The tariff issue remains unresolved. Management expects some minor Q4 impact but does not yet know how U.S. customs will calculate the charge. This is a recurring theme from prior calls, not a new shock. The more important point is that Orion is now paying a small gross-margin price for resilience. Lindell called the marginal impact marginal. For a company with a single product driving nearly half of revenue, that is a trade worth making.

The Org Chart Is the Tell

Orion also used the quarter to reorganize. A new Commercial EVP for International Commercial Operations, a combined Generics and Consumer Health division under global operations, and a Branded Products unit that now includes a European hospital business. CEO Liisa Hurme framed it as the next stage of a strategy that has become less aspirational and more necessary. The company is trying to build commercial and R&D capabilities outside its Finnish base before the Nubeqa patent cliff in 2033. The pipeline is starting to support that story. Orion moved its first biologic, ODM-216, into Phase I; it is a bispecific antibody in advanced solid tumors. Management also hinted at another Phase I program this year. ODM-212 remains wholly owned and self-funded into Phase III, but it was not the star of this call; the fresh pipeline language is biologics and the first large molecule. Even the artificial intelligence discussion was deliberately deflationary -- Hurme noted Orion has used AI in discovery for almost a decade, so this is not a new narrative, just a useful tool.

What Remains Unresolved

Orion still has a concentration problem, and management knows it. Asked how Nubeqa cash is being deployed before the patent cliff, Hurme pointed to a rising R&D budget, new capabilities, and in-licensing. “we are using that cash also building new capabilities in R&D and on different commercial fronts ... there are a lot of activities ongoing to prepare for the 2030s and 2040s.” — Liisa Hurme, Chief Executive Officer · 2026-10-28 That is the right answer, but it is still a promise rather than a number. The quarter also had softer edges. Branded Products grew almost 11%, led by Easyhaler and Women's Health, but Generics was down 3.4% on a tough comparative, and Animal Health was flat because shipments to the Middle East and Africa slipped. Fermion was excellent, and the Hanko Plant 3 is ramping ahead of schedule after the water damage. None of these change the central story. They simply remind you that Orion is not only a Nubeqa royalty stream; it is a portfolio company using a windfall to buy time and optionality. The stock-moving question is whether the market will pay for that optionality before the DASL-HiCaP opt-in economics are visible. Today, Orion is still priced as a Nubeqa royalty story with a wide guidance range. The early DASL-HiCaP win, the U.S. contract-manufacturing move, and the org reset are the first credible signs that management is trying to change that. The risk is that investors extrapolate the clinical win before the financial terms are disclosed. The opportunity is that the quiet rewiring is happening earlier than the patent clock requires.